Duorui pharmaceutical: it plans to invest 5.6 million yuan to establish a holding subsidiary, hairuidi pharmaceutical
Dorui pharmaceutical announced that the company and Hubei Nanyao Xinda Pharmaceutical Co., Ltd. jointly funded the establishment of Hubei hairuidi Pharmaceutical Co., Ltd. Hairuidi pharmaceutical has a registered capital of 8 million yuan. Among them, dorui pharmaceutical subscribed 5.6 million yuan, accounting for 70.00%, and Nanyao Xinda 2.4 million yuan, accounting for 30.00%. The company's investment in hairuidi pharmaceutical comes from its own funds. After the establishment of hairuidi pharmaceutical, it will become the holding subsidiary of the company.
This text is a result of machine translation.
Related companies：
Briefing Jun 21, 2022 10:24 AM
· Consumer Discretionary
The United States and Morocco hold joint military exercises
In-depth
Technology
INMO: No Wires, No Limits, Pure Reality
In the realm of technology today, Augmented Reality (AR) has consistently captured our attention as one of the revolutionary technologies with the potential to reshape our way of life. INMO, (Chinese: 影目科技), one of the frontrunners in the AR glasses domain, has recently unveiled a paradigm-shifting AR eyewear product INMO Go, earning widespread attention.
Nov 28, 2023 06:33 AM
Briefing Jun 09, 2022 08:38 AM
· Consumer Staples
First round of coke price increase
Jan 06, 2023 08:30 AM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Briefing May 16, 2022 09:50 PM
Wang Yi held a video meeting with the new foreign minister of the Republic of Korea Park Chun
Insight
Technology
Consumer Electronics: ESG Emerging as a Hidden Highlight
In the face of the global consumer electronics industry in the cold, the future is more than relying on technological iteration and consumer upgrades, ESG and sustainable is providing new possibilities for the development of the industry.
Nov 30, 2023 10:11 PM
Insight
Briefing Jan 23, 2022 02:29 PM
· Financials
CITIC Securities: the "emotional bottom" is approaching the "market bottom"
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Insight
In-depth